EV-302: The 3.5-year update shows that enfortumab vedotin plus pembrolizumab maintains durable survival benefit over chemotherapy in advanced urothelial carcinoma

Genitourinary Cancer

Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial

Ann Oncol

Powles TB, Van der Heijden MS, Loriot Y, Bedke J, Valderrama BP, Iyer G, Kikuchi E, Hoffman-Censits J, Vulsteke C, Drakaki A, Rausch S, Arafat W, Park SH, Swami U, Li JR, Duran I, Gorla S, Homet Moreno B, Yu X, Lu YT, Gupta S

doi: 10.1016/j.annonc.2025.05.536

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Lancet Oncol

Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T

doi: 10.1016/S1470-2045(25)00158-5

WCLC 2025

Lung, Respiratory and Thoracic Cancer

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

SPECIAL REPORT

Gynecologic Cancer

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer

Lung, Respiratory and Thoracic Cancer

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

Lung Cancer

Tang Y, Du W, Zhang X, Yang X, Zhou Y, Fu S, Zhang L, Hong S

doi: 10.1016/j.lungcan.2025.108855

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

Int J Cancer

Niedersuess-Beke D, Mayrhofer K, Krauter J, Franke J, Vais D, Pallauf M, Kiesl D, Luger F, Pfuner J, Terbuch A, Bauernhofer T, Spielgelberg J, Banner A, Aufderklamm S, Wiesinger C, Schnabel S, Gampenrieder SP, Mühlmann J, Vallet S, Weibrecht S, Stoiber F, Andalibi H, Fajkovic H, Taghizadeh H, Miechowiecki J, Taedcke R, Heintel D, Shariat SF, Pichler M, Hilbe W, Pichler R

doi: 10.1002/ijc.70203

CHICAGO 2026

Genitourinary Cancer

ENGOT-EN6-NSGO/GOG-3031/RUBY: Post hoc analyses show sustained survival benefit with dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer

CHICAGO 2026

Breast Cancer

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

Gastrointestinal Cancer

Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma

Ann Oncol

Chen YX, Jin Y, Chen YK, Cui C, Yao J, Zhang Y, Li M, Cao G, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Luo X, Zhang X, Xie H, Zou J, Xu RH, Wang ZX, Wang F, JUPITER-06 investigators

doi: 10.1016/j.annonc.2026.01.005

Related content

Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

Establishing Pembrolizumab Plus Chemotherapy as a New Standard for dMMR Endometrial Cancer

Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis

Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

ENGOT-EN6-NSGO/GOG-3031/RUBY: Post hoc analyses show sustained survival benefit with dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer

KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC

Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma